Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qinhang Wu has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Comparative efficacy of CLDN18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma: a meta-analysis of single-arm trials

    by Yue Yuan, Hongkai Yan, Qinhang Wu

    Summary Objective To compare the efficacy and safety of different Claudin (CLDN)18.2-directed regimens in advanced gastric/gastroesophageal junction adenocarcinoma. Methods PubMed, Web of Science, CNKI, and Wanfang databases were searched up to June 2026. Single-arm trials evaluating CLDN18.2-targeted gastric/gastroesophageal junction adenocarcinoma therapies were included. Meta-analysis was performed to pool objective response rate (ORR), disease control rate (DCR), median progression-free survival (mPFS), and safety outcomes. Results Ten studies (710 patients) were included. The pooled mPFS was 4.19 months (95% CI 2.90–5.49), the pooled ORR was 30.3% (95% CI 14.8%–48.1%), and the pooled DCR was 78.5% (95% CI 61.2%–92.1%). Subgroup analyses by treatment type revealed substantial efficacy differences. Zolbetuximab monotherapy showed limited activity (mPFS 1.84 months, ORR 4.8%, DCR 37.9%), which improved markedly when combined with chemotherapy (mPFS 6.61 months, ORR 63.7%, DCR 95.6%). Antibody–drug conjugates (ADCs) achieved notable efficacy in pretreated patients (mPFS 5.31 months, ORR 36.7%, DCR 84.3%). Chimeric antigen receptor T-cell (CAR-T) therapy demonstrated substantial anti-tumor activity (mPFS 5.80 months, ORR 54.2%, DCR 96.1%), but the evidence was based on a single study and should be considered preliminary. Conclusion Zolbetuximab plus chemotherapy is the preferred strategy for patients eligible for chemotherapy. ADCs represent a viable option for patients with chemotherapy resistance or intolerance. Zolbetuximab monotherapy has limited efficacy and should be used sparingly. CAR-T showed promising activity but remains investigational.

  • A Review of Traditional Chinese Medicine for Triple Negative Breast Cancer and the Pharmacological Mechanisms

    by Qinhang Wu, Hongkai Yan, Ziyi Kang

    Triple negative breast cancer (TNBC) is an aggressive subtype of breast cancer. Conventional treatment options for TNBC often have limited efficacy and significant side effects. In recent years, traditional Chinese medicine (TCM) has shown promising results in the treatment of TNBC. TCMs include herb combinations that have synergistic effects to regulate homeostasis in the body, reduce tumor resistance, and improve patient quality of life. At present, three main TCM methods are used to treat TNBC in the clinic: strengthening the body’s resistance, dispelling phlegm, and removing cancer toxins. This paper reviews the theories and mechanisms of each in TNBC treatment. The method of strengthening the body’s resistance emphasizes enhancing the body’s original Qi to fight against pathogenic factors; the method of dispelling phlegm seeks to eliminate phlegm stagnation and alleviate the burden on affected organs; the method of removing cancer toxins focuses on detoxification and detumescence to remove the toxic elements associated with TNBC. Although these methods treat TNBC from different etiologies, they have achieved good therapeutic effects and represent an important academic approach: That is, to cure the disease with a comprehensive view of the body and restore the balance of Yin and Yang. This knowledge lays a foundation for the future development and reasonable application of TCM in the clinic.


  • Triptolide Reduces MDA‐MB‐231 Cell Metastasis by Attenuating Epithelial‐Mesenchymal Transition through the ROCK/PTEN/Akt Axis

    by Qinhang Wu, Xuejiao Leng, Xuelin Ma, Qixuan Xu, Ruijun Ni, Yang Pan, Zhuolin Jin, Muhammad Kalim

    Triple‐negative breast cancer (TNBC) is a highly heterogeneous and invasive subtype of breast cancer. The prognosis of TNBC is poor because of its high distant metastasis rate. Triptolide is a type of diterpene trioxide natural compound with potential anti‐tumor activities. This study explored the metastatic inhibitory effect of triptolide on MDA‐MB‐231 cells and its underlying mechanism. Triptolide suppressed cell proliferation and induced cell apoptosis in a time‐ and dose‐dependent manner. Low doses of triptolide (0‐8 nM) reduced the migration and invasion capabilities of MDA‐MB‐231 cells. Triptolide decreased ROCK1, p‐Akt, N‐cadherin, vimentin and MMP‐9 expressions, but increased PTEN and E‐cadherin expressions on protein and mRNA levels. Furthermore, the down‐regulation of ROCK1 expression in MDA‐MB‐231 cells after being treated by triptolide could be rescued by ROCK1 specific inhibitor Y27632. Molecular docking showed that triptolide and Y27632 shared the same active center of ROCK1 protein. This article‘s findings taken together showed that ROCK1 is the primary target of triptolide, which can cause cell apoptosis and inhibit the epithelial‐mesenchymal transition of MDA‐MB‐231 cells.


  • Open Access

    Inhibitory Effect of Salvia miltiorrhiza Extract and Its Active Components on Cervical Intraepithelial Neoplastic Cells

    by Xuejiao Leng, Hongfei Kan, Qinhang Wu, Cunyu Li, Yunfeng Zheng, Guoping Peng

    The effective treatment of cervical intraepithelial neoplasia (CIN) can prevent cervical cancer. Salvia miltiorrhiza is a medicinal and health-promoting plant. To identify a potential treatment for CIN, the effect of S. miltiorrhiza extract and its active components on immortalized cervical epithelial cells was studied in vitro. The H8 cell was used as a CIN model. We found that S. miltiorrhiza extract effectively inhibited H8 cells through the CCK8 method. An HPLC–MS analysis revealed that S. miltiorrhiza extract contained salvianolic acid H, salvianolic acid A, salvianolic acid B, monomethyl lithospermate, 9‴-methyl lithospermate B, and 9‴-methyl lithospermate B/isomer. Salvianolic acid A had the best inhibitory effect on H8 cells with an IC50 value of 5.74 ± 0.63 μM. We also found that the combination of salvianolic acid A and oxysophoridine had a synergistic inhibitory effect on H8 cells at molar ratios of 4:1, 2:1, 1:1, 1:2, and 1:4, with salvianolic acid A/oxysophoridine = 1:2 having the best synergistic effect. Using Hoechst33342, flow cytometry, and Western blotting analysis, we found that the combination of salvianolic acid A and oxysophoridine can induce programmed apoptosis of H8 cells and block the cell cycle in the G2/M phase, which was correlated with decreased cyclinB1 and CDK1 protein levels. In conclusion, S. miltiorrhiza extract can inhibit the growth of H8 cells, and the combination of salvianolic acid A (its active component) and oxysophoridine has a synergistic inhibitory effect on H8 cells and may be a potential treatment for cervical intraepithelial neoplasia.